Domestic biosimilar gives hope to lung cancer patients
The nation’s first biosimilar of Bevacizumab, a lung cancer drug, has been approved by the National Medical Products Administration. The domestically-made product will reduce dependence on imported medicine, cutting costs.
Bevacizumab blocks blood vessel growth in tumors and has been the only choice for patients for the past decade.
To find a cheaper alternative with similar effects, Dr Han Baohui from Shanghai Chest Hospital led the research team on the biosimilar.
The biosimilar and imported medicine were found to have the same effect, causing great interest around the world.